Cargando…
Psychedelic microdosing benefits and challenges: an empirical codebook
BACKGROUND: Microdosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms. According to media reports, microdosing has grown in popularity, yet the scientific literature...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617883/ https://www.ncbi.nlm.nih.gov/pubmed/31288862 http://dx.doi.org/10.1186/s12954-019-0308-4 |
_version_ | 1783433793592360960 |
---|---|
author | Anderson, Thomas Petranker, Rotem Christopher, Adam Rosenbaum, Daniel Weissman, Cory Dinh-Williams, Le-Anh Hui, Katrina Hapke, Emma |
author_facet | Anderson, Thomas Petranker, Rotem Christopher, Adam Rosenbaum, Daniel Weissman, Cory Dinh-Williams, Le-Anh Hui, Katrina Hapke, Emma |
author_sort | Anderson, Thomas |
collection | PubMed |
description | BACKGROUND: Microdosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms. According to media reports, microdosing has grown in popularity, yet the scientific literature contains minimal research on this practice. There has been limited reporting on adverse events associated with microdosing, and the experiences of microdosers in community samples have not been categorized. METHODS: In the present study, we develop a codebook of microdosing benefits and challenges (MDBC) based on the qualitative reports of a real-world sample of 278 microdosers. RESULTS: We describe novel findings, both in terms of beneficial outcomes, such as improved mood (26.6%) and focus (14.8%), and in terms of challenging outcomes, such as physiological discomfort (18.0%) and increased anxiety (6.7%). We also show parallels between benefits and drawbacks and discuss the implications of these results. We probe for substance-dependent differences, finding that psilocybin-only users report the benefits of microdosing were more important than other users report. CONCLUSIONS: These mixed-methods results help summarize and frame the experiences reported by an active microdosing community as high-potential avenues for future scientific research. The MDBC taxonomy reported here informs future research, leveraging participant reports to distil the highest-potential intervention targets so research funding can be efficiently allocated. Microdosing research complements the full-dose literature as clinical treatments are developed and neuropharmacological mechanisms are sought. This framework aims to inform researchers and clinicians as experimental microdosing research begins in earnest in the years to come. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12954-019-0308-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6617883 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66178832019-07-22 Psychedelic microdosing benefits and challenges: an empirical codebook Anderson, Thomas Petranker, Rotem Christopher, Adam Rosenbaum, Daniel Weissman, Cory Dinh-Williams, Le-Anh Hui, Katrina Hapke, Emma Harm Reduct J Research BACKGROUND: Microdosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms. According to media reports, microdosing has grown in popularity, yet the scientific literature contains minimal research on this practice. There has been limited reporting on adverse events associated with microdosing, and the experiences of microdosers in community samples have not been categorized. METHODS: In the present study, we develop a codebook of microdosing benefits and challenges (MDBC) based on the qualitative reports of a real-world sample of 278 microdosers. RESULTS: We describe novel findings, both in terms of beneficial outcomes, such as improved mood (26.6%) and focus (14.8%), and in terms of challenging outcomes, such as physiological discomfort (18.0%) and increased anxiety (6.7%). We also show parallels between benefits and drawbacks and discuss the implications of these results. We probe for substance-dependent differences, finding that psilocybin-only users report the benefits of microdosing were more important than other users report. CONCLUSIONS: These mixed-methods results help summarize and frame the experiences reported by an active microdosing community as high-potential avenues for future scientific research. The MDBC taxonomy reported here informs future research, leveraging participant reports to distil the highest-potential intervention targets so research funding can be efficiently allocated. Microdosing research complements the full-dose literature as clinical treatments are developed and neuropharmacological mechanisms are sought. This framework aims to inform researchers and clinicians as experimental microdosing research begins in earnest in the years to come. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12954-019-0308-4) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-10 /pmc/articles/PMC6617883/ /pubmed/31288862 http://dx.doi.org/10.1186/s12954-019-0308-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Anderson, Thomas Petranker, Rotem Christopher, Adam Rosenbaum, Daniel Weissman, Cory Dinh-Williams, Le-Anh Hui, Katrina Hapke, Emma Psychedelic microdosing benefits and challenges: an empirical codebook |
title | Psychedelic microdosing benefits and challenges: an empirical codebook |
title_full | Psychedelic microdosing benefits and challenges: an empirical codebook |
title_fullStr | Psychedelic microdosing benefits and challenges: an empirical codebook |
title_full_unstemmed | Psychedelic microdosing benefits and challenges: an empirical codebook |
title_short | Psychedelic microdosing benefits and challenges: an empirical codebook |
title_sort | psychedelic microdosing benefits and challenges: an empirical codebook |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617883/ https://www.ncbi.nlm.nih.gov/pubmed/31288862 http://dx.doi.org/10.1186/s12954-019-0308-4 |
work_keys_str_mv | AT andersonthomas psychedelicmicrodosingbenefitsandchallengesanempiricalcodebook AT petrankerrotem psychedelicmicrodosingbenefitsandchallengesanempiricalcodebook AT christopheradam psychedelicmicrodosingbenefitsandchallengesanempiricalcodebook AT rosenbaumdaniel psychedelicmicrodosingbenefitsandchallengesanempiricalcodebook AT weissmancory psychedelicmicrodosingbenefitsandchallengesanempiricalcodebook AT dinhwilliamsleanh psychedelicmicrodosingbenefitsandchallengesanempiricalcodebook AT huikatrina psychedelicmicrodosingbenefitsandchallengesanempiricalcodebook AT hapkeemma psychedelicmicrodosingbenefitsandchallengesanempiricalcodebook |